FDA approves Aurobindo’s Lunesta generic

DAYTON, N.J. — The Food and Drug Administration has approved Aurobindo Pharma’s generic of Lunesta (ezopiclone), the company announced Wednesday. The drug is indicated to treat insomnia. 

 

Aurobindo’s generic will be available in 1-, 2- and 3-mg dosage strengths. The drug had an estimated market size of $78.8 million for the 12 months ended August 2016.